RT Journal Article
SR Electronic
T1 Covid-19 is a leading cause of death in children and young people ages 0-19 years in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.23.22275458
DO 10.1101/2022.05.23.22275458
A1 Flaxman, Seth
A1 Whittaker, Charles
A1 Semenova, Elizaveta
A1 Rashid, Theo
A1 Parks, Robbie M
A1 Blenkinsop, Alexandra
A1 Unwin, H Juliette T
A1 Mishra, Swapnil
A1 Bhatt, Samir
A1 Gurdasani, Deepti
A1 Ratmann, Oliver
YR 2022
UL http://medrxiv.org/content/early/2022/05/25/2022.05.23.22275458.abstract
AB Covid-19 has caused more than 1 million deaths in the US, including at least 1,433 deaths among children and young people (CYP) aged 0-19 years. Deaths among US CYP are rare in general, and so we argue here that the mortality burden of Covid-19 in CYP is best understood in the context of all other causes of CYP death. Using publicly available data from the National Center for Health Statistics, and comparing to mortality in 2019, the immediate pre-pandemic period, we find that Covid-19 is a leading cause of death in CYP aged 0-19 years in the US, ranking #9 among all causes of deaths, #5 in disease related causes of deaths (excluding accidents, assault and suicide), and #1 in deaths caused by infectious / respiratory diseases. Due to the impact of mitigations such as social distancing and our comparison of a single disease (Covid-19) to groups of causes such as deaths from pneumonia and influenza, these rankings are likely conservative lower bounds. Our findings underscore the importance of continued vaccination campaigns for CYP over 5 years of age in the US and for effective Covid-19 vaccines for under 5 year olds.Competing Interest StatementThe authors have declared no competing interest.Funding StatementES and SF acknowledge funding from the EPSRC (EP/V002910/2), OR from the MRC (MR/V038109/1). SM and SB acknowledge funding from the Novo Nordisk Young Investigator Award (NNF20OC0059309). CW acknowledges funding from the MRC DTP that supports his PhD studies (Award Ref 1975152). This research was funded in whole or in part by EPSRC (EP/V002910/2). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript (AAM) version arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY open available human data that were originally located at https://wonder.cdc.gov/ and https://data.cdc.gov/api/views/3apk-4u4fI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were originally obtained from https://wonder.cdc.gov/ and https://data.cdc.gov/api/views/3apk-4u4f and are available online at https://github.com/flaxter/covid19pediatric/ https://wonder.cdc.gov/ https://data.cdc.gov/api/views/3apk-4u4f https://github.com/flaxter/covid19pediatric/